Data (30, 31) from preclinical and clinical studies suggest that HER2 may eventually assume the driving role in tumor progression by serving as an alternate survival pathway or by lowering the level of ER, so rendering the tumor less estrogen-sensitive. This evidence concerns the gene ESR1 and neoplasm.